| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FRAT1 |
| Uniprot No | Q92837 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-279aa |
| 氨基酸序列 | MPCRREEEEE AGEEAEGEEE EEDSFLLLQQ SVALGSSGEV DRLVAQIGET LQLDAAQHSP ASPCGPPGAP LRAPGPLAAA VPADKARSPA VPLLLPPALA ETVGPAPPGV LRCALGDRGR VRGRAAPYCV AELATGPSAL SPLPPQADLD GPPGAGKQGI PQPLSGPCRR GWLRGAAASR RLQQRRGSQP ETRTGDDDPH RLLQQLVLSG NLIKEAVRRL HSRRLQLRAK LPQRPLLGPL SAPVHEPPSP RSPRAACSDP GASGRAQLRT GDGVLVPGS |
| 分子量 | 29.0 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FRAT1蛋白的3篇文献示例(注：文献为模拟生成，非真实存在)：
---
1. **文献名称**：*FRAT1 promotes oncogenic β-catenin signaling in colorectal cancer*
**作者**：van Es, J.H. et al.
**摘要**：研究报道了重组人FRAT1蛋白通过抑制GSK3β活性，稳定β-catenin，激活Wnt信号通路，促进结直肠癌细胞增殖和侵袭的分子机制。
2. **文献名称**：*Structural insights into the interaction between FRAT1 and GSK3β*
**作者**：Bechtel, S. et al.
**摘要**：利用X射线晶体学解析了重组人FRAT1蛋白与GSK3β的结合结构，揭示其通过保守的磷酸化位点阻断GSK3β对β-catenin的降解作用。
3. **文献名称**：*Overexpression of recombinant human FRAT1 induces chemoresistance in breast cancer cells*
**作者**：Li, X. et al.
**摘要**：实验表明，重组人FRAT1蛋白在乳腺癌细胞中异常表达可激活PI3K/AKT通路，降低细胞凋亡率，增强癌细胞对紫杉醇的耐药性。
---
**说明**：以上文献及内容为学术场景模拟，实际研究需参考真实数据库(如PubMed)。如需真实文献，可检索关键词“FRAT1”“Wnt signaling”“cancer”或“GSK3β interaction”。
Recombinant human FRAT1 (Frequently Rearranged in Advanced T-cell lymphomas 1) protein is a key regulator in the Wnt/β-catenin signaling pathway, which plays critical roles in embryonic development, stem cell maintenance, and oncogenesis. The FRAT1 gene, located on chromosome 10q24.1. encodes a cytoplasmic protein that interacts with Glycogen Synthase Kinase-3β (GSK3β) to prevent the phosphorylation and subsequent degradation of β-catenin, thereby stabilizing its levels and promoting Wnt signaling activation. Overexpression of FRAT1 has been linked to various cancers, including colorectal, hepatocellular, and breast carcinomas, as dysregulated Wnt signaling often drives uncontrolled cell proliferation.
Originally identified for its involvement in T-cell lymphoma due to chromosomal rearrangements, FRAT1’s role extends beyond hematological malignancies. It is also implicated in neural development and maintaining pluripotency in embryonic stem cells. Recombinant FRAT1 protein, typically produced in Escherichia coli or mammalian expression systems, retains functional properties essential for studying its molecular interactions and pathway modulation. Researchers utilize this recombinant form to dissect FRAT1’s binding affinities with GSK3β and β-catenin, explore its oncogenic mechanisms, and develop targeted therapies. Its applications include in vitro assays, structural analysis, and screening for inhibitors that could block aberrant Wnt signaling in cancer. Studies on recombinant FRAT1 continue to advance understanding of its dual roles in physiological homeostasis and disease progression.
×
